The Siglec-sialic acid-axis is a target for innate immunotherapy of glioblastoma https://www.biorxiv.org/content/10.1101/2022.11.07.515406
The Siglec-sialic acid-axis is a target for innate immunotherapy of glioblastoma https://www.biorxiv.org/content/10.1101/2022.11.07.515406
@biorxivpreprint Exiting new #glycotime preprint from Heinz Laubli and coworkers @UnivBasel, Siglec E in mouse (closest to Siglec 9 in human) dampens the immune response to GBM, knockout limits tumor growth and synergizes with checkpoint blockade.